Some US states are considering or have already dropped Medicaid coverage of GLP-1 weight loss drugs, while others are debating the issue. The decision to drop coverage appears to be affecting various groups, including Medicaid recipients and public workers. The fate of coverage for these drugs remains uncertain, with some lawmakers advocating for continued coverage and others seemingly hesitant to provide it.